Login

Financial Snapshot

Revenue
TTM
$55.90M
Gross Margin
TTM
63.19%
Net Income
TTM
-$9.169M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
580.03%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$13.09M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$8.990M

Stock Price

Loading...
Market Cap: $161.21 Million

About Apyx Medical Inc

Apyx Medical Inc (NASDAQ: APYX) is a medical device company that develops and sells energy-based surgical equipment for the cosmetic surgery market. Revenue comes from selling capital equipment generators and single-use handpieces and accessories to surgeons, supported by an international distributor network. The company's core technology is Helium Plasma Technology, commercialized through its Surgical Aesthetics segment, which targets procedures such as liposuction and surgical lifts. Manufacturing of generators and single-use handpieces occurs at a wholly owned subsidiary, Apyx Bulgaria, EOOD, located in Sofia, Bulgaria, with contract component manufacturing sourced from Ningbo, China. As of December 31, 2025, the company employed 205 full-time employees worldwide. Apyx carried approximately $31.7 million in cash and cash equivalents as of December 31, 2025, with a Perceptive Credit Agreement carrying financial covenants tied to Surgical Aesthetics segment revenue targets of $37.0 million for full-year 2025 and $52.4 million for 2026.

Revenue model
Transactional sales of capital equipment generators and single-use handpieces and accessories to cosmetic surgeons, sold through a direct sales force in the U.S. and an international distributor network. The company also generates revenue through OEM generators and related accessories manufactured at its Bulgarian subsidiary.
Products and services
Helium Plasma Technology-based surgical aesthetic generators, AYON equipment (commercially launched in the second half of 2025), single-use handpieces and accessories, and OEM generators and related accessories.
Customers and end markets
Cosmetic and aesthetic surgeons performing procedures including liposuction and surgical lifts. End market is the global cosmetic surgery market, with demand driven by social media influence, appearance trends, and disposable income growth. Per the ISAPS 2024 Global Survey, liposuction remains a top-two aesthetic surgical procedure globally.
Value-chain role
Medical device manufacturer and seller. Designs products internally, manufactures at Apyx Bulgaria in Sofia, sources contract components from Ningbo, China, and distributes through a direct U.S. sales force and international distributor network. Also provides clinical support specialists and surgeon training programs.
Geographic exposure
Operations in the United States and Bulgaria (Apyx Bulgaria, EOOD, Sofia). Contract component manufacturing in Ningbo, China. International sales through distributor network. Apyx Bulgaria also distributes directly to customers in certain international markets.

Source: SEC 10-K, filed 2026-03-10

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Accelerate Diagnostics, Inc Accuray Inc Apollo Endosurgery, Inc. CVRx, Inc. RetinalGenix Technologies Inc SeaSpine Holdings Corp Sensus Healthcare Inc Tactile Systems Technology Inc Zomedica Corp

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support